Studies currently recruiting within EpSSG are:
this is a study for all non metastatic rhabdomyosarcoma. It provides treatment guidelines for treatment of patients in low risk, standard risk and very high risk sub groups (as defined by the EpSSG prognostic classification) and incorporates a randomised phase III trial comparing standard chemotherapy using the IVA combination (ifosfamide, vincristine and actinomycin D) with an experimental arm including IVA with doxorubicin (the IVADo combination) in high risk sub groups.
(EudraCT Number: 2005-000217-35)
this is a study for nearly all types of non metastatic non-rhabdo soft tissue sarcoma (NRSTS). It is structured in three sections.
Section 1 is a single arm study of treatment for synovial sarcoma incorporating risk stratified guidance for the use of chemotherapy (with ifosfamide and doxorubicin) and local therapy (surgery and/or radiotherapy).
Section 2 provides risk stratified guidelines for the treatment of ‘adult type’ NRSTS occurring in children and young people (for example: fibrosarcoma, malignant peripheral nerve sheath tumour, liposarcoma, leiomyosarcoma, epithelioid sarcoma, and others). This incorporates guidance about local therapy and the use of chemotherapy (utilising ifosfamide and doxorubicin) as appropriate.
Section 3 consists of a series of disease specific guidelines for the treatment of rare, more typically paediatric NRSTS (for example: infantile fibrosarcoma, malignant rhabdoid tumour).
(EudraCT Number: 2005-001139-31)
this is a pharmaceutical company regulatory study sponsored by Hoffman-La Roche comparing conventional chemotherapy utilizing the IVADo combination (as given in the RMS 2005 study) with or without Bevacizumab® in patients with metastatic rhabdomyosarcoma and in selected metastatic NRSTS
VIT – this is a randomised phase II study of the combination vincristine and irinotecan with or without temozolomide (VI or VIT) in patients with refractory (unresponsive) or relapsed (recurrent) rhabdomyosarcoma.
(EudraCT Number: 2010-023135-42)
Full details of these studies are available to EpSSG members in the Members’ section of this website
Please refer to the principal investigator and listed EpSSG Centres